| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy |
|
言語 |
en |
| 作成者 |
Mitani, Yoshitsugu
Oue, Naohide
Matsumura, Shunji
Yoshida, Kazuhiro
Noguchi, Tsuyoshi
Ito, Masanori
Tanaka, Shinji
Kuniyasu, Hiroki
Kamata, Nobuyuki
Yasui, Wataru
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
Copyright (c) 2007 Nature Publishing Group. |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Reg IV |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
apoptosis |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
5-fluorouracil |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
serum tumor marker |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
SAGE |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
gastric cancer |
| 主題 |
|
|
主題Scheme |
NDC |
|
主題 |
490 |
| 内容記述 |
|
|
内容記述 |
Regenerating gene family, member 4 (Reg IV), a secreted protein, is overexpressed in several cancers, including gastric cancer (GC). In the present study, we measured Reg IV levels in sera from patients with GC by enzyme-linked immunosorbent assay. We also examined the effect of forced Reg IV expression on the apoptotic susceptibility to 5-fluorouracil (5-FU). Forced expression of Reg IV inhibited 5-FU-induced apoptosis. Induction of Bcl-2 and dihydropyrimidine dehydrogenase was involved in inhibition of apoptosis. Among 36 GC patients treated with a combination chemotherapy of low-dose 5-FU and cisplatin, all 14 Reg IV-positive patients showed no change or disease progression. The serum Reg IV concentration was similar between healthy individuals (mean±s.e., 0.52±0.05 ng/ml) and patients with chronic-active gastritis (0.36±0.09 ng/ml). However, the serum Reg IV concentration in presurgical GC patients was significantly elevated (1.96±0.17 ng/ml), even at stage I. The diagnostic sensitivity of serum Reg IV (36.1%) was superior to that of serum carcinoembryonic antigen (11.5%) or carbohydrate antigen 19-9 (13.1%). These results indicate that expression of Reg IV is a marker for prediction of resistance to 5-FU-based chemotherapy in patients with GC. Serum Reg IV represents a novel biomarker for GC. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Nature Publishing Group |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AO |
|
出版タイプResource |
http://purl.org/coar/version/c_b1a7d7d4d402bcce |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1038/sj.onc.1210215 |
| 関連情報 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
17237819 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
http://dx.doi.org/10.1038/sj.onc.1210215 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0950-9232 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA10687380 |
| 開始ページ |
|
|
開始ページ |
4383 |
| 書誌情報 |
Oncogene
Oncogene
巻 26,
号 30,
p. 4383-4393,
発行日 2007
|
| 旧ID |
20727 |
Oncogene_26-30_4383.pdf (591.8 KB)
